Is GNRRF or NOBL a better dividend investment in 2026?

GNRRF currently yields 43.96% with a 5% 5-year dividend growth rate. NOBL yields 2.17% with 5% growth. The better choice depends on your goal: GNRRF offers higher current income.

What is the dividend yield difference between GNRRF and NOBL?

GNRRF has a forward dividend yield of 43.96% ($2.00/share annually). NOBL yields 2.17% ($2.27/share annually). The yield gap is 41.79 percentage points.

Home › Compare › GNRRF vs NOBL

GNRRF vs NOBL: Dividend Comparison 2026

GNRRF yields 43.96% · NOBL yields 2.17%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 GNRRF wins by $264.1K in total portfolio value

INVESTMENT

TIME HORIZON10 years

GNRRF

● Live price

43.96%

Share price

$4.55

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$287.0K

Annual income

$52,411.25

Full GNRRF calculator →

NOBL

● Live price

2.17%

Share price

$104.67

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.9K

Annual income

$249.78

Full NOBL calculator →

Portfolio growth — GNRRF vs NOBL

📍 GNRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	GNRRF	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, GNRRF + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

GNRRF pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNRRF

Annual income on $10K today (after 15% tax)

$3,736.26/yr

After 10yr DRIP, annual income (after tax)

$44,549.56/yr

NOBL

Annual income on $10K today (after 15% tax)

$184.52/yr

After 10yr DRIP, annual income (after tax)

$212.31/yr

At 15% tax rate, GNRRF beats the other by $44,337.25/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNRRF + NOBL for your $10,000?

GNRRF: 50%NOBL: 50%

100% NOBL50/50100% GNRRF

Portfolio after 10yr

$154.9K

Annual income

$26,330.52/yr

Blended yield

17.00%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNRRF buys

NOBL buys

No recent congressional trades found for GNRRF or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricGNRRFNOBL

Forward yield	43.96% ✓	2.17%
Annual dividend / share	$2.00	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$287.0K ✓	$22.9K
Annual income after 10y	$52,411.25 ✓	$249.78
Total dividends collected	$221.7K ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: GNRRF vs NOBL ($10,000, DRIP)

Year	GNRRF Portfolio	GNRRF Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$15,096	$4,395.60	$10,917	$217.08	+$4.2K → GNRRF
2	$22,354	$6,201.34	$11,903	$221.48	+$10.5K → GNRRF
3	$32,501	$8,582.21	$12,962	$225.68	+$19.5K → GNRRF
4	$46,437	$11,661.61	$14,099	$229.68	+$32.3K → GNRRF
5	$65,260	$15,572.20	$15,319	$233.49	+$49.9K → GNRRF
6	$90,281	$20,452.54	$16,628	$237.10	+$73.7K → GNRRF
7	$123,043	$26,443.04	$18,033	$240.53	+$105.0K → GNRRF
8	$165,338	$33,681.45	$19,539	$243.78	+$145.8K → GNRRF
9	$219,210	$42,298.12	$21,154	$246.86	+$198.1K → GNRRF
10	$286,966	$52,411.25	$22,884	$249.78	+$264.1K → GNRRF

GNRRF vs NOBL: Complete Analysis 2026

GNRRF — Stock

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

Full GNRRF Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this GNRRF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNRRF vs SCHD GNRRF vs JEPI GNRRF vs O GNRRF vs KO GNRRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.